ArticleThe American journal of managed care2019
Deprescribing in the context of multiple providers: understanding patient preferences.
Article in The American journal of managed care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effective deprescribing strategies for reducing potentially inappropriate medications and improving economic outcomes in community-based settings: a systematic review and meta-analysis.BMC health services research · 2026Pooled it
- Bridging the Gap: Systematic Review of Strategies to Facilitate Post-Discharge Continuity of In-Hospital Medication Changes in Older Adults.Drugs & aging · 2026Pooled it
- Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review.BMJ open · 2022Pooled it
- How Willing Are Patients or Their Caregivers to Deprescribe: a Systematic Review and Meta-analysis.Journal of general internal medicine · 2021Pooled it
- 'Do I actually even need all these tablets?' A qualitative study exploring deprescribing decision-making for people in receipt of palliative care and their family members.Palliative medicine · 2025Article
- Engagement of outpatient providers in a deprescribing trial for hospitalized older patients transitioning to post-acute care facilities.Health literacy and communication open · 2025Article
- Article
- Deprescribing medications among patients with multiple prescribers: A socioecological model.Journal of the American Geriatrics Society · 2024Article
- Current Landscape and Future Directions of Deprescribing and Polypharmacy Practices in Jordan.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Older Adult Perspectives on Statin Continuation and Discontinuation in Primary Cardiovascular Disease Prevention: A Mixed-Methods Study.Patient preference and adherence · 2024Article
- Patient Perceptions of Opioids and Benzodiazepines and Attitudes Toward Deprescribing.Drugs & aging · 2023Article
- Deprescribing, shared decision-making, and older people: perspectives in primary care.Journal of pharmaceutical policy and practice · 2023Review
- Weighing the necessities and concerns of deprescribing among older ambulatory patients and primary care trainees: a qualitative study.BMC primary care · 2023Article
- Exploring Older Adult Health Literacy in the Day-to-Day Management of Polypharmacy and Making Decisions About Deprescribing: A Mixed Methods Study.Health literacy research and practice · 2023Article
- Experience of hospital-initiated medication changes in older people with multimorbidity: a multicentre mixed-methods study embedded in the OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM) trial.BMJ quality & safety · 2022Article
- Care coordination needs for deprescribing benzodiazepines and benzodiazepine receptor agonists.Research in social & administrative pharmacy : RSAP · 2022Article
- Article
- Research status and hotspots of medication safety in older adults: A bibliometric analysis.Frontiers in public health · 2022Review
- Patient values and preferences on polypharmacy and deprescribing: a scoping review.International journal of clinical pharmacy · 2021Article
- Primary care clinician and community pharmacist perceptions of deprescribing.Journal of the American Geriatrics Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesDeprescribing could reduce the risk of harm from inappropriate medications. We characterized patients' acceptance of deprescribing recommendations from pharmacists, primary care providers (PCPs), and specialists relative to the original prescriber's professional background. STUDY
designSecondary analysis of national Patient Perceptions of Discontinuation survey responses from Veterans Affairs (VA) primary care patients with 5 or more prescriptions.
methodsWe created 4 relative deprescribing authority (RDA) outcome groups from responses to 2 yes/no (Y/N) items: (1) "Imagine…a specialist…prescribed a medicine. Would you be comfortable if your PCP told you to stop...it?" and (2) "Imagine…your VA PCP prescribed a medicine. Would you be comfortable if a VA clinical pharmacist [Pharm] told you to stop…it?" Multinomial regression associated patient factors with RDA.
resultsRespondents (n = 803; adjusted response rate, 52%) were predominantly men (85%) and older than 65 years (60%). A total of 281 (38%) respondents said no to both questions (PCP-N/Pharm-N) and 146 (20%) said yes to both (PCP-Y/Pharm-Y). A total of 155 (21%) said no to a PCP stopping a specialist's medicine but yes to a pharmacist stopping a PCP's (PCP-N/Pharm-Y). A total of 153 (21%) said that a PCP could stop a specialist's medication but a pharmacist could not stop a PCP's (PCP-Y/Pharm-N). In adjusted models (reference, PCP-N/Pharm-N), those with greater medication concerns were more likely to respond PCP-Y/Pharm-Y (odds ratio [OR], 1.45; 95% CI, 1.09-1.92). Those with more interest in shared decision making were more likely to respond PCP-N/Pharm-Y (OR, 1.41; 95% CI, 1.04-1.92). Those with greater trust in their PCP were less likely to respond PCP-N/Pharm-Y (OR, 0.52; 95% CI, 0.34-0.81) but more likely to respond PCP-Y/Pharm-N (OR, 2.16; 95% CI, 1.31-3.56) or PCP-Y/Pharm-Y (OR, 1.83; 95% CI, 1.13-2.98).
conclusionsUnderstanding patient preferences of RDA can facilitate effective design and implementation of deprescribing interventions.
Indexed as
Identifiers
30986016PMC6788284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.